Stephen Basil Thomas sold $1.4M of CLYM
director at Climb Bio, Inc.. 100,000 shares at an average of $13.67, traded Sep 15, 2026, filed Sep 17, 2026.
Score components
- +15RoleDirector
- +25Trade size$1.4M at market
- +5Share of holdings soldSold 18% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-394357, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -100,000 | $13.67 | $1.4M | 467,969 | 25 d ago |
Related signals
Other insiders at Climb Bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | CLYMbuy Climb Bio, Inc. | Ra Capital Management, L.p. director, owner | $755k 314,561 shares | +10% | |
| 13Weak | Climb Bio, Inc. | Aoife Brennan President and CEO | $25k 20,618 shares | -30% | |
| 0Weak | Climb Bio, Inc. | Emily Pimblett SVP, Finance & CAO | $1,540 1,242 shares | -6% | |
| 0Weak | Climb Bio, Inc. | Emily Pimblett SVP, Finance & CAO | $1,571 1,199 shares | -7% | |
| 0Weak | Climb Bio, Inc. | Emily Pimblett CHIEF ACCOUNTING OFFICER | $2,495 1,235 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.